177 related articles for article (PubMed ID: 36185185)
21. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains.
Chang H; Trieu Y; Qi X; Jiang NN; Xu W; Reece D
Leuk Res; 2011 Jan; 35(1):95-8. PubMed ID: 20537706
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
23. At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China.
Shen M; Yang G; Li X; Geng C; Huang Z; Chen W
Leuk Lymphoma; 2021 Dec; 62(12):2992-3001. PubMed ID: 34219587
[TBL] [Abstract][Full Text] [Related]
24. [Influence of Combination with 1q21 Amplification or-No in Patients with Newly Diagnosed MM on the Clinical Effecacy of Bortezomib-based induction chemotherapy and Long-Term Prognosis of Patients].
Gu WW; Wang JS; Mu K; Ren G
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1251-1255. PubMed ID: 32798407
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.
Jian Y; Chen X; Zhou H; Zhu W; Liu N; Geng C; Chen W
Medicine (Baltimore); 2016 May; 95(19):e3521. PubMed ID: 27175647
[TBL] [Abstract][Full Text] [Related]
26. The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sides.
Xu J; Xu T; Yang Y; Wang W; Li J; Ren Y; Gu S; Chen C; Wei Z; Zhuang J; Wang Z; Ji L; Cheng L; Wang W; Cheng Z; Ke Y; Yuan L; Liu P
Leuk Lymphoma; 2020 Oct; 61(10):2351-2364. PubMed ID: 32519901
[TBL] [Abstract][Full Text] [Related]
27. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
Mohan M; Gong Z; Ashby TC; Al Hadidi S; Thanendrarajan S; Schinke C; Alapat D; Shaughnessy JD; Zhan F; van Rhee F; Sawyer JR; Tian E; Zangari M
Cancer; 2023 Aug; 129(16):2491-2498. PubMed ID: 37282609
[TBL] [Abstract][Full Text] [Related]
28. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
[TBL] [Abstract][Full Text] [Related]
29. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.
Wang YT; Bao L; Chu B; Chen XH; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH
J Clin Lab Anal; 2022 Jul; 36(7):e24375. PubMed ID: 35353920
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of daratumumab in newly diagnosed multiple myeloma patients with 1q21 gain.
Iriuchishima H; Saito A; Mihara M; Terasaki Y; Matsumoto A; Isoda A; Furukawa Y; Matsumoto M
Int J Hematol; 2024 Mar; ():. PubMed ID: 38551778
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of 1q21 Gain in Multiple Myeloma.
Chen D; Zhou D; Xu J; Zhou R; Ouyang J; Chen B
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):e159-e164. PubMed ID: 30685183
[TBL] [Abstract][Full Text] [Related]
32. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
An G; Li Z; Tai YT; Acharya C; Li Q; Qin X; Yi S; Xu Y; Feng X; Li C; Zhao J; Shi L; Zang M; Deng S; Sui W; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Anderson KC; Qiu L
Clin Cancer Res; 2015 May; 21(9):2148-56. PubMed ID: 25652456
[TBL] [Abstract][Full Text] [Related]
33. ARNT/HIF-1β links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma.
Wu C; Yang T; Liu Y; Lu Y; Yang Y; Liu X; Liu X; Ye L; Sun Y; Wang X; Li Q; Yang P; Yu X; Gao S; Kumar S; Jin F; Dai Y; Li W
Cancer Med; 2018 Aug; 7(8):3899-3911. PubMed ID: 29926531
[TBL] [Abstract][Full Text] [Related]
34. [Clinical Efficacy and Prognosis of Double-Hit Multiple Myeloma Patients with Deletion P53 Treated with Regimen Based on Bortezomib].
Wang DM; Chen YY; Meng Z; Zhang YX; Guo SQ; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1221-1227. PubMed ID: 32798402
[TBL] [Abstract][Full Text] [Related]
35. The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.
Tang HKK; Fung CY; Morgan GJ; Kumar S; Siu L; Ip HWA; Yip SF; Lau KNH; Lau CK; Lee H; Leung KH; Kho B; Wong H; Ngai C; Hwang YY; Sim J; Kwong YL; Chim CS
Ther Adv Hematol; 2022; 13():20406207221082043. PubMed ID: 35465644
[TBL] [Abstract][Full Text] [Related]
36. Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications.
Kastritis E; Migkou M; Dalampira D; Gavriatopoulou M; Fotiou D; Roussou M; Kanellias N; Ntanasis-Stathopoulos I; Malandrakis P; Theodorakakou F; Sevastoudi A; Eleutherakis-Papaiakovou E; Triantafyllou T; Terpos E; Katodritou E; Dimopoulos MA
Am J Hematol; 2022 Sep; 97(9):1142-1149. PubMed ID: 35731917
[TBL] [Abstract][Full Text] [Related]
37. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
[TBL] [Abstract][Full Text] [Related]
38. Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma.
Hanamura I
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445467
[TBL] [Abstract][Full Text] [Related]
39. Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
Kiyota M; Kobayashi T; Fuchida S; Yamamoto-Sugitani M; Ohshiro M; Shimura Y; Mizutani S; Nagoshi H; Sasaki N; Nakayama R; Chinen Y; Sakamoto N; Uchiyama H; Matsumoto Y; Horiike S; Shimazaki C; Kuroda J; Taniwaki M
Int J Hematol; 2012 May; 95(5):516-26. PubMed ID: 22426624
[TBL] [Abstract][Full Text] [Related]
40. p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain).
Teoh PJ; An O; Chung TH; Vaiyapuri T; Raju A; Hoppe MM; Toh SHM; Wang W; Chan MC; Fullwood MJ; Jeyasekharan AD; Tergaonkar V; Chen L; Yang H; Chng WJ
Oncogene; 2022 Apr; 41(14):2106-2121. PubMed ID: 35190641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
